## Abstract ## BACKGROUND Highβdose methotrexate (HDMTX) is used frequently in combination regimens that include nephrotoxic chemotherapy. The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and
Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion
β Scribed by Wang, Yeu-Ming ;Kim, Pyong-Young ;Lantin, Erlinda ;van Eys, D. Catherine ;Romsdahl, Marvin M. ;Sutow, Wataru W.
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 507 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Plasma methotrexate (MTX) concentrations were quantitated in 34 patients after 127 highβdose (35β350 mg/kg) infusions with citrovorum factor rescue. Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy. However, similar trends have not been observed when 48β and 72βhour samples were analyzed. Clinical toxicity was not serious when the methotrexate level in plasma was < 4.5 Γ 10^β6^ M at 48 hours after the start of a sixβhour infusion in children. A minimal fourβhour steadyβstate methotrexate plasma level can be maintained during a sixβhour infusion. Children excrete methotrexate at a faster rate than adults; the halfβlife of MTX during the first phase of plasma clearance curve is one hour shorter in children. Urinary analyses have indicated that substantial methotrexate is metabolized. The chemical nature of these components has not been identified. Further, the urinary metabolic profiles varied among patients.
π SIMILAR VOLUMES
A pharmacokinetic study was performed in plasma and cerebrospinal fluid (CSF) of patients suffering from brain tumors to describe the disposition of methotrexate. An open three-compartment model was developed to fit together the data obtained in plasma and CSF. The pharmacokinetic parameters obtaine
The authors thank Dr. James Balow at the National Institute of Diabetes, and Digestive, and Kidney Disorders for helpful suggestions during the preparation of this article. This article is dedicated to the memory of Dr. Charles Pratt, who devoted his extraordinary career to the treatment of children